(3S,7S)-24-(4-(4-(((1S,2R)-1-benzamido-3-(((2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-diacetoxy-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2-yl)oxy)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)-5,13-dioxo-4,6,12,14-tetraazatetracosane-1,3,7-tricarboxylic acid

ID: ALA4448685

Chembl Id: CHEMBL4448685

PubChem CID: 155520424

Max Phase: Preclinical

Molecular Formula: C76H98N8O23

Molecular Weight: 1491.65

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCCc4cn(CCCCCCCCCCNC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)nn4)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O

Standard InChI:  InChI=1S/C76H98N8O23/c1-45-54(42-76(101)65(106-69(97)50-31-20-15-21-32-50)63-74(6,55(87)41-56-75(63,44-102-56)107-47(3)86)64(91)61(103-46(2)85)59(45)73(76,4)5)104-70(98)62(60(48-27-16-13-17-28-48)81-66(92)49-29-18-14-19-30-49)105-58(90)35-26-33-51-43-84(83-82-51)40-25-12-10-8-7-9-11-23-38-77-71(99)78-39-24-22-34-52(67(93)94)79-72(100)80-53(68(95)96)36-37-57(88)89/h13-21,27-32,43,52-56,60-63,65,87,101H,7-12,22-26,33-42,44H2,1-6H3,(H,81,92)(H,88,89)(H,93,94)(H,95,96)(H2,77,78,99)(H2,79,80,100)/t52-,53-,54-,55-,56+,60-,61+,62+,63-,65-,74+,75-,76+/m0/s1

Standard InChI Key:  RIRDZYIBEDNDFM-AEFAMJKCSA-N

Alternative Forms

  1. Parent:

    ALA4448685

    ---

Associated Targets(Human)

A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK-293T (167025 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PC-3 (62116 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CWR22R (2180 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LNCaP (8286 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
WI-38 VA13 (346 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1491.65Molecular Weight (Monoisotopic): 1490.6745AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Machulkin AE, Skvortsov DA, Ivanenkov YA, Ber AP, Kavalchuk MV, Aladinskaya AV, Uspenskaya AA, Shafikov RR, Plotnikova EA, Yakubovskaya RI, Nimenko EA, Zyk NU, Beloglazkina EK, Zyk NV, Koteliansky VE, Majouga AG..  (2019)  Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.,  29  (16): [PMID:31248772] [10.1016/j.bmcl.2019.06.035]

Source